Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (02268.HK) [1] Core Views - The company's 2025 performance met expectations, with revenue reaching 5,944 million RMB (+46.7%), gross profit of 2,139 million RMB (+72.5%), and a gross margin of 36.0% (+5.4%) [1] - Adjusted net profit for 2025 was 1,559 million RMB (+69.9%), with an adjusted profit margin of 26.2% (+3.6 percentage points) [1] - The company is expected to enter a commercialization phase, supported by a solid backlog of orders and a strong market position in the bioconjugate drug CRDMO sector [7] Financial Summary - Revenue projections for 2026, 2027, and 2028 are 8,043 million RMB, 10,503 million RMB, and 13,716 million RMB, respectively, with year-on-year growth rates of 35.3%, 30.6%, and 30.6% [3] - The net profit for the same years is projected to be 2,013 million RMB, 2,639 million RMB, and 3,371 million RMB, with growth rates of 36.0%, 31.1%, and 27.7% [3] - The earnings per share (EPS) is expected to increase from 1.18 RMB in 2025 to 2.68 RMB in 2028 [3] Market Position and Growth Drivers - The company has solidified its leading position in the global bioconjugate drug CRDMO market, increasing its market share to approximately 24% and signing a record 70 iCMC projects in 2025 [7] - The company’s overseas revenue accounted for 85% of total revenue in 2025, with significant demand from the North American market [7] - The company has a robust order backlog, with unfulfilled orders growing by 50.3% year-on-year to 1.5 billion USD by the end of 2025, ensuring long-term growth [7] Capacity Expansion and Strategic Moves - The company is advancing its global dual-plant capacity layout, with significant investments in production capabilities, including a recent acquisition of 31 million HKD to enhance DP production capacity [7] - The establishment of a one-stop production base in Wuxi and the upcoming GMP release of the Singapore facility are expected to meet diverse compliance production needs for clients [7]

Investment Rating - The report maintains a "Recommendation" rating for WuXi AppTec (02268.HK) [1] Core Insights - The company achieved a revenue of 5,944 million RMB in 2025, representing a year-on-year growth of 46.7%. The gross profit reached 2,139 million RMB, with a gross margin of 36.0%, an increase of 5.4 percentage points. The adjusted net profit was 1,559 million RMB, reflecting a growth of 69.9% [1][7] - The revenue structure is continuously optimized, with a significant increase in orders, particularly in the second half of 2025, where revenue reached 3,243 million RMB, a year-on-year increase of 35.9%. The company’s overseas revenue accounted for 85% of total revenue, driven by strong demand in the North American market [7] - WuXi AppTec has solidified its leading position in the global bioconjugate drug CRDMO market, increasing its market share to approximately 24% in 2025. The company signed 70 new iCMC projects, reaching a total of 252 projects in hand, which supports future growth [7] - The company is advancing its global dual-plant capacity layout, with significant progress in its Wuxi base and the acquisition of Dongyao Pharmaceutical for 3.1 billion HKD, adding 8 million bottles/year of DP capacity [7] - The revenue forecasts for 2026-2028 are 8,043 million RMB, 10,503 million RMB, and 13,716 million RMB, with expected growth rates of 35.3%, 30.6%, and 30.6% respectively. The net profit forecasts are 2,013 million RMB, 2,639 million RMB, and 3,371 million RMB, with growth rates of 36.0%, 31.1%, and 27.7% [7]

Core Viewpoint - WuXi AppTec (02268) has seen a significant stock price increase following its positive earnings forecast for 2025, indicating strong growth potential in the XDC CRDMO industry driven by rising demand for integrated services and CMC orders [2][5]. Company Summary - WuXi AppTec's stock price rose by 7.54% to HKD 62.75, with a trading volume of HKD 301 million [2][5]. - The company issued an earnings forecast for 2025, leading to a slight downward adjustment in revenue and adjusted net profit projections for 2025-2027 by 1-3%, estimating revenues of RMB 5.88 billion, 8.28 billion, and 11.11 billion, and adjusted net profits of RMB 1.60 billion, 2.45 billion, and 3.42 billion respectively, corresponding to a CAGR of 38% and 46% for 2025-2027 [2][5]. Industry Summary - In the first two months of 2026, there were 25 financing events in the global XDC sector, a significant increase from 18 events in the same period of 2025, indicating a growing trend in investment activity [2][5]. - The number of BD transactions for XDC candidate drugs has remained stable, with a substantial increase in total upfront payments, reflecting a robust market environment [2][5]. - Since the beginning of 2024, there has been a gradual increase in the number of financing events, BD transactions, and upfront payment totals in the XDC field, suggesting a sustained demand improvement in the CRDMO industry [2][5].

Core Viewpoint - WuXi AppTec (02268) has seen a significant stock price increase, with a rise of over 8% during trading, currently up 6.6% at HKD 62.2, with a trading volume of HKD 253 million. The company has issued a positive earnings forecast for 2025, leading to a slight adjustment in revenue and adjusted net profit predictions for 2025-2027 by 1-3% [1] Group 1: Financial Forecasts - The adjusted revenue forecasts for 2025-2027 are set at RMB 5.88 billion, 8.28 billion, and 11.11 billion respectively, while the adjusted net profit forecasts are RMB 1.60 billion, 2.45 billion, and 3.42 billion, corresponding to a compound annual growth rate (CAGR) of 38% and 46% for the respective years [1] - The strong growth is primarily attributed to the rapid increase in comprehensive CMC orders, particularly from late-stage clinical and commercialization phase contributions [1] Group 2: Market Trends - In the first two months of 2026, there were 25 financing events in the global XDC sector, a significant increase from 18 events in the same period of 2025 [1] - The number of BD transactions for XDC candidate drugs has remained stable, with a substantial increase in total upfront payments [1] - Since the beginning of 2024, there has been a gradual increase in the number of financing events, BD transactions, and total upfront payments in the XDC field, indicating sustained market activity [1] Group 3: Industry Position - The ongoing activity in financing and BD transactions is expected to further enhance downstream demand in the XDC CRDMO industry [1] - WuXi AppTec, as a leading company with strong technical capabilities and integrated delivery capabilities, is well-positioned to benefit from this important trend and expand its market share [1]

Core Viewpoint - WuXi AppTec (02268) has seen a significant stock price increase, with a rise of over 8% during trading, currently up 6.6% at HKD 62.2, with a trading volume of HKD 253 million. The company has issued a positive earnings forecast for 2025, indicating strong growth potential in the coming years [1]. Group 1: Earnings Forecast and Adjustments - WuXi AppTec has released an earnings forecast for 2025, prompting CMB International to slightly adjust its revenue and adjusted net profit predictions for 2025-2027 down by 1-3%, estimating revenues of RMB 5.88 billion, 8.28 billion, and 11.11 billion for the respective years, and adjusted net profits of RMB 1.6 billion, 2.45 billion, and 3.42 billion [1]. - The projected compound annual growth rate (CAGR) for revenues from 2025 to 2027 is strong at 38% and 46%, primarily driven by rapid growth in comprehensive CMC orders, particularly from late-stage clinical and commercialization orders [1]. Group 2: Market Trends and Opportunities - In the first two months of 2026, there were 25 financing events in the global XDC sector, a significant increase from 18 events in the same period of 2025, indicating a growing trend in investment activity [1]. - The number of BD transactions for XDC candidate drugs has remained stable, with a substantial increase in total upfront payments, reflecting a robust market environment [1]. - Since the beginning of 2024, there has been a gradual increase in the number of financing events, BD transactions, and total upfront payments in the XDC field, suggesting a sustained demand improvement in the XDC CRDMO industry [1]. - WuXi AppTec, as a leading company with strong technical capabilities and integrated delivery capabilities, is well-positioned to benefit from these trends and expand its market share [1].